Drug Profile
BMS 185857
Latest Information Update: 18 Jan 2008
Price :
$50
*
At a glance
- Originator Bristol-Myers Squibb
- Class Antineoplastics
- Mechanism of Action Farnesyltranstransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 18 Jan 2005 Discontinued - Preclinical for Cancer in USA (unspecified route)
- 12 Feb 2001 Profile reviewed but no significant changes made
- 06 Oct 1997 No-Development-Reported for Cancer in USA (Unknown route)